Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CPB1 | P15086 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17287194 | 0.86 | MAPT (0.59) | KLK7KLK5MAPTSIRT2SIRT1 | |
| SCHEMBL18791213 | 0.86 | MAPT (0.59) | KLK7KLK5MAPTSIRT2SIRT1 | |
| SCHEMBL18791195 | 0.86 | MAPT (0.56) | KLK7KLK5MAPTSIRT2SIRT1 | |
| SCHEMBL13599690 | 0.85 | MAPT (0.58) | KLK7KLK5MAPTSIRT2SIRT1 | |
| SCHEMBL1328864 | 0.85 | MAPT (0.51) | KLK7KLK5MAPT | |
| SCHEMBL12287162 | 0.85 | KLK7 (0.49) | KLK7KLK5MAPTSIRT2SIRT1 | |
| SCHEMBL2584353 | 0.85 | KLK7 (0.49) | KLK7KLK5MAPTSIRT2SIRT1 | |
| SCHEMBL1330132 | 0.84 | KLK7 (0.47) | KLK7KLK5MAPTSIRT2SIRT1 | |
| SCHEMBL30902907 | 0.83 | MAPT (0.65) | KLK7KLK5MAPTSIRT2SIRT1 | |
| SCHEMBL30902797 | 0.83 | MAPT (0.62) | KLK7KLK5MAPTSIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238020-B2 | Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20130090379-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Tapentadol Prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2011133178-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PHENOL-MODIFIED TAPENTADOL PRODRUG | PHARMACOFORE, INC (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090379-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Tapentadol Prodrug | CYP2C9, ACHE, COMT | KLK7 871/4885KLK5 1107/4885MAPT 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.